Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.48 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.48 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PGK1 | P00558 | 1/20 | 0.41 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9120834 | 0.98 | HRH3 (0.52) | CARM1PRMT6PRMT8HRH3CYP2C19 | |
| SCHEMBL21727231 | 0.98 | HRH3 (0.52) | CARM1PRMT6PRMT8HRH3CYP2C19 | |
| SCHEMBL13661321 | 0.94 | HRH3 (0.48) | CARM1PRMT6PRMT8HRH3CYP2C19 | |
| SCHEMBL13766333 | 0.93 | HRH3 (0.52) | CARM1PRMT6PRMT8HRH3CYP2C19 | |
| SCHEMBL17525471 | 0.92 | CARM1 (0.42) | CARM1PRMT6PRMT8HRH3CYP2C19 | |
| SCHEMBL13178479 | 0.91 | HRH3 (0.56) | CARM1PRMT6PRMT8HRH3CYP2C19 | |
| SCHEMBL21572857 | 0.91 | — | — | |
| SCHEMBL4640495 | 0.91 | CYP2C19 (0.50) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL7326006 | 0.90 | HRH3 (0.60) | CARM1PRMT6PRMT8HRH3CYP2C19 | |
| SCHEMBL13660804 | 0.88 | HRH3 (0.52) | CARM1PRMT6PRMT8HRH3CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399303-A1 | Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same | UNIV YALE (US) | 2023-12-14 | — | — | US | disclosed |
| US-10336721-B2 | Biaryltriazole inhibitors of macrophage migration inhibitory factor | YALE UNIVERSITY (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180179176-A1 | BIARYLTRIAZOLE INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR | UNIV YALE (US) | 2018-06-28 | — | — | US | disclosed |
| US-9717694-B2 | Peptide/particle delivery systems | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-08-01 | — | — | US | disclosed |
| US-9717694-B2 | Peptide/particle delivery systems | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-08-01 | — | — | US | disclosed |
| US-20160374949-A9 | PEPTIDE/PARTICLE DELIVERY SYSTEMS | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-12-29 | — | — | US | disclosed |
| US-20160333009-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS | GILEAD SCIENCES, INC. | 2016-11-17 | — | — | US | disclosed |
| US-20120114759-A1 | PEPTIDE/PARTICLE DELIVERY SYSTEMS | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120114759-A1 | PEPTIDE/PARTICLE DELIVERY SYSTEMS | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-05-10 | — | — | US | disclosed |
| US-20100081825-A1 | 1-NAPHTHYL ALKYLPIPERIDINE DERIVATIVE | TAISHO PHARMACEUTICAL CO LTD (JP) | 2010-04-01 | — | — | US | disclosed |
| US-20100081825-A1 | 1-NAPHTHYL ALKYLPIPERIDINE DERIVATIVE | TAISHO PHARMACEUTICAL CO LTD (JP) | 2010-04-01 | — | — | US | disclosed |
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
| EP-2108648-A1 | Selected CGRP antagonists, method for their manufacture and use as medicines | Boehringer Ingelheim International GmbH (DE) | 2009-10-14 | — | — | EP | disclosed |
| US-7504391-B2 | Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders | SCHERING CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1268431-B1 | 3-CYANOQUINOLINES,3-CYANO-1,6-NAPHTHYRIDINES, AND 3-CYANO-1,7-NAPHTHYRIDINES AS PROTEIN KINASE INHIBITORS | WYETH CORP (US) | 2007-08-29 | — | — | EP | disclosed |
| US-RE38415-E1 | POLYMERIZATION CATALYSTS SUCH AS N-(3-AMINOPROPYL)PYRROLIDINE USED FOR COPOLYMERIZATION OR CONDENSATION POLYMERIZATION OF POLYURETHANES, POLYUREAURETHANE COPOLYMERS OR POLYUREAS | BAYER AKTIENGESELLSCHAFT (DE) | 2004-02-03 | — | — | US | disclosed |
| EP-0495249-B1 | Use of N-(aminoalkyl)-pyrrolidines as a catalyst for the polyisocyanate-poly-addition process, process for the preparation of polyurethane-ureas | BAYER AG (DE) | 1994-07-27 | — | — | EP | disclosed |
| US-5134217-A | Forming polyurethanes modified with chain extension agents for foams | BAYER AKTIENGESELLSCHAFT (DE) | 1992-07-28 | — | — | US | disclosed |
| EP-0495249-A1 | Use of N-(aminoalkyl)-pyrrolidines as a catalyst for the polyisocyanate-poly-addition process, process for the preparation of polyurethane-ureas | BAYER AG (DE) | 1992-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160374949-A9 | PEPTIDE/PARTICLE DELIVERY SYSTEMS | VEGFA, IAPP, FLT1 | CARM1 4787/4885PRMT6 3542/4885PRMT8 4203/4885 |
| US-20160333009-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS | IDO1, IDO2, INMT | CARM1 160/4885PRMT6 338/4885PRMT8 77/4885 |
| US-10336721-B2 | Biaryltriazole inhibitors of macrophage migration inhibitory factor | MIF, MMP12, CSF1R | CARM1 2581/4885PRMT6 1317/4885PRMT8 1985/4885 |
| US-20100081825-A1 | 1-NAPHTHYL ALKYLPIPERIDINE DERIVATIVE | MCHR1, MCHR2, MC5R | CARM1 1568/4885PRMT6 2692/4885PRMT8 3718/4885 |
| US-20120114759-A1 | PEPTIDE/PARTICLE DELIVERY SYSTEMS | VEGFA, IAPP, FLT1 | CARM1 4787/4885PRMT6 3542/4885PRMT8 4203/4885 |
| US-20180179176-A1 | BIARYLTRIAZOLE INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR | MIF, MMP12, CSF1R | CARM1 2581/4885PRMT6 1317/4885PRMT8 1985/4885 |
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | TIE1, TEK, MATK | CARM1 1393/4885PRMT6 982/4885PRMT8 1135/4885 |
| US-20230399303-A1 | Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same | MIF, MMP12, METAP1 | CARM1 1063/4885PRMT6 217/4885PRMT8 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.